You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for Piroxicam
Piroxicam is an anti-inflammatory; highly selective inhibitor of COX-1 (ratio of IC50 values for COX-2/COX-1 ~ 600).
Technical Data for Piroxicam
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
References for Piroxicam
References are publications that support the biological activity of the product.
Mitchell et al (1995) Cyclooxygenase-2. Regulation and relevance in inflammation. Biochem.Pharmacol. 50 1535 PMID: 7503754
Merck Index 12 7661
View Related Products by Product Action
Keywords: Piroxicam, Piroxicam supplier, Cyclooxygenase, COX-1, inhibitors, inhibits, COX, Oxygenases, Oxidases, 0960, Tocris Bioscience
Citations for Piroxicam
Citations are publications that use Tocris products.
Currently there are no citations for Piroxicam.
Reviews for Piroxicam
There are currently no reviews for this product. Be the first to review Piroxicam and earn rewards!
Have you used Piroxicam?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.